Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Paul A. S. Fishkin"'
Autor:
R. Donald Harvey, Bradley C. Carthon, Cody J. Peer, Abiola Ibraheem, Wei Peng Yong, Elia Martinez, Russell Z. Szmulewitz, Paul A. S. Fishkin, Mark J. Ratain, Chadi Nabhan, Mark Kozloff, Edmund Chiong, Theodore Karrison, Walter M. Stadler, William D. Figg
Purpose Abiraterone acetate (AA) is a standard of care for metastatic castration-resistant prostate cancer (CRPC). Despite a large food effect, AA was administered under fasting conditions in its pivotal trials. We sought to test the hypothesis that
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cfe416710ed0875ee7491b7b85e49a9e
https://europepmc.org/articles/PMC5941614/
https://europepmc.org/articles/PMC5941614/
Autor:
Russell Z. Szmulewitz, Walter M. Stadler, Gregory S. Karczmar, Aytekin Oto, Peter H. O'Donnell, Shannon Towey, Randy F. Sweis, Milica Medved, Paul A. S. Fishkin, Theodore Karrison
Introduction/Background Traditional imaging assessment criteria might not correlate well with clinical benefit from vascular endothelial growth factor pathway-directed therapy in metastatic renal cancer. Preclinical data suggest tumor growth is prece
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a1ff66963e5981fbe57bb92efc1c39c
https://europepmc.org/articles/PMC5315677/
https://europepmc.org/articles/PMC5315677/
Autor:
Abiola Ibraheem, R. Donald Harvey, Wei Peng Yong, Edmund Chiong, William D. Figg, Russell Z. Szmulewitz, Mark J. Ratain, Chadi Nabhan, Mark Kozloff, Peter H. O'Donnell, Bradley C. Carthon, Paul A. S. Fishkin, Walter M. Stadler, Cody J. Peer
Publikováno v:
Journal of Clinical Oncology. 35:176-176
176 Background: AA is a standard of care for the treatment of metastatic CRPC, with an approximate retail cost of $8000/month. Despite a large food effect (~17-fold increase in CMax with a high-fat meal), AA was administered under fasting conditions
Autor:
John W. Kugler, Rose Arrieta, Paul A. S. Fishkin, Everett E. Vokes, Dale R. Shepard, Mark J. Ratain, Nicholas J. Vogelzang, Bruce Brockstein
Publikováno v:
The Prostate Journal. 1:195-202
Hormone refractory prostate cancer (HRPC) will affect more than 40,000 men in the United States in 1999, and only a few drugs have activity in this disease. We studied trimethylcolchicinic acid (TMCA), an oral colchicine derivative, in a Phase II tri
Autor:
Randy F. Sweis, Paul A. S. Fishkin, Peter H. O'Donnell, Aytekin Oto, Russell Z. Szmulewitz, Greg S. Karczmar, Shannon Towey, Walter M. Stadler, Milica Medved
Publikováno v:
Journal of Clinical Oncology. 33:e15623-e15623
e15623 Background: Traditional imaging assessment criteria may not correlate well with clinical benefit from vascular endothelial growth factor pathway directed therapy in RC. DCE-MRI derived Ktran...